1
|
Risi E, Vignoli A, Lisanti C, Biagioni C, Paderi A, Cappadona Sciammetta S, Del Monte F, Moretti E, Sanna G, Livraghi L, Malorni L, Benelli M, Puglisi F, Luchinat C, Tenori L, Biganzoli L. 148P Serum metabolomics based risk assessment of disease recurrence in elderly patients with early breast cancer (eBC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
2
|
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020; 31:1623-1649. [PMID: 32979513 PMCID: PMC7510449 DOI: 10.1016/j.annonc.2020.09.010] [Citation(s) in RCA: 654] [Impact Index Per Article: 163.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 09/15/2020] [Accepted: 09/16/2020] [Indexed: 01/09/2023] Open
Affiliation(s)
- F Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
| | - S Paluch-Shimon
- Sharett Division of Oncology, Hadassah University Hospital, Jerusalem, Israel
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - G Curigliano
- Department of Oncology and Hemato-Oncology, European Institute of Oncology, IRCCS, Division of Early Drug Development, University of Milan, Milan, Italy
| | - M S Aapro
- Breast Center, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - C H Barrios
- Latin American Cooperative Oncology Group (LACOG), Grupo Oncoclínicas, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - G S Bhattacharyya
- Department of Medical Oncology, Salt Lake City Medical Centre, Kolkata, India
| | - L Biganzoli
- Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | - F Boyle
- The Pam McLean Centre, Royal North Shore Hospital, St Leonards, Australia
| | - M-J Cardoso
- Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal; Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- IOB Institute of Oncology, Quiron Group, Madrid & Barcelona, Spain; Department of Oncology, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - N S El Saghir
- Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
| | - M Elzayat
- Europa Donna, The European Breast Cancer Coalition, Milan, Italy
| | - A Eniu
- Interdisciplinary Oncology Service (SIC), Riviera-Chablais Hospital, Rennaz, Switzerland
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | - J Gligorov
- Breast Cancer Expert Center, University Cancer Institute APHP, Sorbonne University, Paris, France
| | - R Haidinger
- Brustkrebs Deutschland e.V., Munich, Germany
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - X Hu
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
| | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - R Kaur
- Breast Cancer Welfare Association Malaysia, Petaling Jaya, Malaysia
| | - B E Kiely
- NHMRC Clinical Trials Centre, Sydney Medical School, Sydney, Australia
| | - S-B Kim
- Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine, Seoul, South Korea
| | - N U Lin
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| | - S A Mertz
- Metastatic Breast Cancer Network, Inverness, USA
| | - S Neciosup
- Department of Medical Oncology, National Institute of Neoplastic Diseases, Lima, Peru
| | - B V Offersen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O Pagani
- Medical School, Geneva University Hospital, Geneva, Switzerland
| | - A Prat
- Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona; Department of Medicine, University of Barcelona, Barcelona
| | - F Penault-Llorca
- Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France; University Clermont Auvergne/INSERM U1240, Clermont-Ferrand, France
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Division of Oncology, Stanford School of Medicine, Stanford, USA
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Research Unit, Belong.Life, Tel Aviv, Israel
| | - T Wiseman
- Department of Applied Health Research in Cancer Care, The Royal Marsden Hospital NHS Foundation Trust, London, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - E P Winer
- Susan Smith Center for Women's Cancers - Breast Oncology Center, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
3
|
Galardi F, Biagioni C, De Luca F, Curigliano G, Minisini A, Bonechi M, Moretti E, Risi E, Migliaccio I, McCartney A, Benelli M, Romagnoli D, Conti V, Biganzoli L, Di Leo A, Malorni L. 6P Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.03.142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
4
|
Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial. Ann Oncol 2019; 29:1748-1754. [PMID: 29893790 DOI: 10.1093/annonc/mdy214] [Citation(s) in RCA: 66] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023] Open
Abstract
Background The activity of palbociclib as a single agent in advanced breast cancer has not been extensively studied, with the only available clinical data limited to heavily pretreated patients. Preclinical data suggests palbociclib may partially reverse endocrine resistance, though this hypothesis has not been evaluated in previous clinical studies. This phase II, open-label, multicenter study examined the activity of palbociclib monotherapy, as well as palbociclib given in combination with the same endocrine therapy (ET) that was received prior to disease progression, in postmenopausal women with moderately pretreated, estrogen receptor-positive, HER2 negative advanced breast cancer. Patients and methods Eligible women with advanced disease which had progressed on one or two prior ETs were randomized 1 : 1 to receive either palbociclib alone, or palbociclib in combination with the ET as previously received. Primary end point was clinical benefit rate (CBR); secondary end points included progression-free survival (PFS). Results Between October 2012 and July 2016, a total of 115 patients were randomized. The CBR was 54% [95% confidence interval (CI): 41.5-63.7] for combination therapy, and 60% (95% CI: 47.8-72.9) for monotherapy. Median PFS was 10.8 months (95% CI: 5.6-12.7) for combination therapy, and 6.5 months (95% CI: 5.4-8.5) for monotherapy [hazard ratio (HR) 0.69; 95% CI: 0.4-1.1, exploratory P-value = 0.12]. Exploratory analyses revealed the PFS advantage for combination therapy was seen in the subgroup of patients who received prior ET for >6 months (HR 0.53; 95% CI: 0.3-0.9, exploratory P-value = 0.02), but not in those who received prior ET for ≤6 months. Conclusion Palbociclib has clinical activity as a single agent in women with moderately pretreated, oestrogen receptor-positive, HER2-negative advanced breast cancer. Palbociclib may have potential to reverse endocrine resistance in patients with a history of previous durable response to ET. Clinical trial information NCT02549430.
Collapse
Affiliation(s)
- L Malorni
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy.
| | - G Curigliano
- Division of Early Drug Development, Department of Haematology and Haemato-Oncology, Istituto Europeo di Oncologia, University of Milan, Milan, Italy
| | - A M Minisini
- Department of Oncology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy
| | - S Cinieri
- Medical Oncology Department, ASL Brindisi, Brindisi, Italy
| | - C A Tondini
- Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - K D'Hollander
- International Drug Development Institute, Louvain-La-Neuve, Belgium
| | - G Arpino
- Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples
| | - A Bernardo
- Medical Oncology Department, ICS Maugeri IRCCS, Pavia, Italy
| | - A Martignetti
- Oncology Department, Azienda USL Toscana Sud Est, Hospital Alta Val D'Elsa, Poggibonsi Siena, Italy
| | - C Criscitiello
- Division of Early Drug Development, Istituto Europeo di Oncologia, Milan, Italy
| | - F Puglisi
- Medical Oncology and Cancer Prevention Unit, IRCCS, CRO National Cancer Institute, Aviano; Department of Medicine, University of Udine, Udine, Italy
| | - M Pestrin
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - G Sanna
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - E Moretti
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - E Risi
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - C Biagioni
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - A McCartney
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - L Boni
- Clinical Trial Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence, Italy
| | - M Buyse
- International Drug Development Institute, San Francisco, USA
| | - I Migliaccio
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - L Biganzoli
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - A Di Leo
- "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Prato, Italy
| |
Collapse
|
5
|
Cardoso MJ, Biganzoli L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Kovacs T, Wyld L. Corrigendum to "About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position" [Breast 46 (August 2019) 95-96]. Breast 2019; 48:103. [PMID: 31706464 DOI: 10.1016/j.breast.2019.10.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Affiliation(s)
- M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
| | - L Biganzoli
- Breast Unit, Nuovo Ospedale di Prato, Prato, Italy
| | - I T Rubio
- Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
| | - M Leidenius
- Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Helsinki, Finland
| | - G Curigliano
- IEO, European Institute of Oncology IRCCS, Italy; University of Milano, Milan, Italy
| | - B Cutuli
- Institut du Cancer Courlancy, Reims, France
| | | | - T Kovacs
- Surgical Oncologist at Guy's and St. Thomas' NHS Foundation Trust, London, UK
| | - L Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| |
Collapse
|
6
|
Cardoso MJ, Wyld L, Rubio IT, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L. Corrigendum to "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants" [Breast 44 (April 2019) 90-93]. Breast 2019; 48:102. [PMID: 31706463 DOI: 10.1016/j.breast.2019.10.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Nova Medical School, Lisbon, Portugal.
| | - L Wyld
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - I T Rubio
- Breast Surgical Oncology, Clínica Universidad de Navarra, Madrid, Universidad de Navarra, Spain
| | - M Leidenius
- Breast Surgery Unit, Comprehensive Cancer Center Helsinki University Hospital, Helsinki, Finland
| | - G Curigliano
- IEO, European Institute of Oncology IRCCS, Italy; University of Milano, Milan, Italy
| | - B Cutuli
- Institut du Cancer Courlancy, Reims, France
| | | | - L Biganzoli
- Breast Unit, Nuovo Ospedale di Prato, Prato, Italy
| |
Collapse
|
7
|
Donato SD, Vignoli A, Mori E, Tenori L, Malorni L, Cantafio S, Mottino G, Becheri D, Mccartney A, Biagioni C, De Monte F, Leo AD, Luchinat C, Biganzoli L. A metabolomic recurrence score for risk-stratification of elderly patients (pts) with early colorectal cancer (eCRC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Cazzaniga M, Pronzato P, Del Mastro L, Natoli C, Montemurro F, Bisagni G, Blasi L, Turletti A, Giordano M, Biganzoli L, Michelotti A, Garrone O, Marchetti P, Riccardi F, Bernardo A, Livi L, Cognetti F, Donadio M, Romagnoli E, Mustacchi G. Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Biganzoli L, Brain E, Malorni L, Risi E, Regan M. Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.109] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Cardoso M, Biganzoli L, Rubio I, M L, G C, B C, L M, Kovacs T, Wyld L. About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position. Breast 2019; 46:95-96. [DOI: 10.1016/j.breast.2019.05.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Accepted: 05/02/2019] [Indexed: 11/28/2022] Open
|
11
|
Cardoso M, Wyld L, Rubio I, Leidenius M, Curigliano G, Cutuli B, Marotti L, Biganzoli L. EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. Breast 2019; 44:90-93. [DOI: 10.1016/j.breast.2019.01.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 01/25/2019] [Accepted: 01/25/2019] [Indexed: 12/24/2022] Open
|
12
|
Cazzaniga ME, Blasi L, Pronzato P, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bologna A, Bria E, Mustacchi G. Abstract P4-13-04: Not presented. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-13-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the conference.
Citation Format: Cazzaniga ME, Blasi L, Pronzato P, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bologna A, Bria E, Mustacchi G. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-13-04.
Collapse
Affiliation(s)
- ME Cazzaniga
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Blasi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - P Pronzato
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M Giordano
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - O Garrone
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M Donadio
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Del Mastro
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Livi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - C Natoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Michelotti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Turletti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - F Riccardi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - M De Laurentiis
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - P Marchetti
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - F Montemurro
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - E Romagnoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - S De Placido
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - L Biganzoli
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - A Bologna
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - E Bria
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| | - G Mustacchi
- ASST Monza, Monza, Italy; University of Trieste, Trieste, Italy; AOU San Martino, Genova, Italy; ASST Lariana, Como, Italy; Osp S. Croce, Cuneo, Italy; Az. Sanitaria Osped. Molinette, Torino, Italy; University of Firenze, Firenze, Italy; University of Chieti, Chieti, Italy; AOU Santa Chiara, Pisa, Italy; Osp. Evangelico Valdese, Torino, Italy; Osp. Cardarelli, Napoli, Italy; Istituto Pascale, Napoli, Italy; La Sapienza Università di Roma, Roma, Italy; Istituto di Candiolo - FPO (IRCCS), Torino, Italy; Oncologia AV3, Macerata, Italy; Università Federico II, Napoli, Italy; Nuovo Ospedale S. Stefano, Prato, Italy; Az. Osp. Reggio Emilia, Reggio Emilia, Italy; Università Cattolica del Sacro Cuore, Fondazione Policlinico 'A. Gemelli', Roma, Italy; Presidio Ospedaliero Civico e Benfratelli, Palermo, Italy
| |
Collapse
|
13
|
Rubio I, Wyld L, Kovacs T, Leidenius M, Kolacinska A, Marotti L, Bianca S, Cardoso M, Biganzoli L, Audisio R. Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA International Survey. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
14
|
Leo AD, Biganzoli L, Bohm S, Lupi G, Oriana S, Riboldi G, Spatti G, Vicario G, Di Re F, Bajetta E. An Intensive Treatment with Mitoxantrone and Ifosfamide in Second-Line Therapy of Epithelial Ovarian Cancer. Tumori 2018; 80:443-7. [PMID: 7900234 DOI: 10.1177/030089169408000607] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Aims and background Both mitoxantrone (DHAD) and ifosfamide (IFO) have given promising results when administered as single agents in advanced ovarian cancer pretreated with platinum compounds. The aim of this I.T.M.O. group pilot trial was to evaluate, in a selected population of ovarian cancer patients, the efficacy and tolerability of the following intensive second-line regimen: DHAD, 12 mg/m2 i.v., day 1; IFO, 4,000 mg/m2 i.v., days 1 and 2; Mesna, 800 mg/m2 i.v. t.i.d., days 1 and 2. Filgrastim (5 μg/kg/day i.m.) was given from day 6 to day 19 to reduce the expected neutropenia. Cycles were repeated every 21 days. Methods Nineteen platinum-pre-treated patients were enrolled and 14 were evaluated for tumor response; the disease of 5 patients was not measurable clinically or radiologically. Results Seven responses were observed (3 CRs), with a median response duration of 5 months. The median time to treatment failure and overall survival for all 19 patients was respectively 8 and 13 months. Anemia was observed in all of the treated patients (grade 3–4 in 9 cases). Only 6 of the 19 patients ended the five planned cycles of chemotherapy without any delay. Conclusions Although DHAD plus IFO induced a considerable number of objective responses, the limited response duration time to treatment failure, and overall survival as well as the reported side effects suggest that this is not a recommended regimen for the palliative treatment of ovarian cancer patients undergoing second-line chemotherapy.
Collapse
Affiliation(s)
- A D Leo
- Division of Medical Oncology B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. Ann Oncol 2018; 29:1634-1657. [PMID: 30032243 PMCID: PMC7360146 DOI: 10.1093/annonc/mdy192] [Citation(s) in RCA: 761] [Impact Index Per Article: 126.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology (ESO), European Society for Medical Oncology (ESMO) and Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
| | - E Senkus
- European Society for Medical Oncology (ESMO) and Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - A Costa
- European School of Oncology, Milan, Italy
| | | | - M Aapro
- Oncology Department, Clinique de Genolier, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Institut Gustave Roussy, Villejuif, France
| | - N Harbeck
- Breast Centre, Department of Obstetrics and Gynaecology, University of Munich (LMU), Munich, Germany
| | - B Aguilar Lopez
- Direction Office, ULACCAM (Union Latinoamericana Contra el Cáncer de la Mujer), Mexico DF, Mexico
| | - C H Barrios
- Department of Oncology, PURCS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology-Pathology, Karolinska Institute & University Hospital, Stockholm, Sweden
| | - L Biganzoli
- European Society of Breast Cancer Specialists (EUSOMA) and Department of Medical Oncology, Nuovo Ospedale di Prato - Istituto Toscano Tumori, Prato, Italy
| | | | - M J Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation and Nova Medical School, Lisbon, Portugal
| | - L A Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA
| | - J Cortés
- Department of Oncology, Vall d' Hebron University, Barcelona, Spain
| | - G Curigliano
- Division of Early Drug Development, Department of Oncology and Hemato-Oncology, European Institute of Oncology, University of Milano, Milano, Italy
| | - V Diéras
- Gynaecology and Breast Department, Centre Eugène Marquis, Rennes, France
| | - N S El Saghir
- Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - A Eniu
- Breast Cancer Department, Cancer Institute Ion Chiricuta, Cluj-Napoca, Romania
| | - L Fallowfield
- SHORE-C, Brighton & Sussex Medical School, University of Sussex, Brighton, UK
| | - P A Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- Medical Oncology Department, BC Cancer Agency, Vancouver, Canada
| | | | - B Kaufman
- Department of Oncology, Sheba Medical Center, Ramat Gan, Israel
| | - S Koppikar
- Department of Medical Oncology, Bombay Hospital Institute of Medical Sciences, Mumbai, India
| | - I E Krop
- Breast Oncology Center Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - G Nakigudde
- Advocacy Department, UWOCASO (Uganda Women's Cancer Support Organization), Kampala, Uganda
| | - B V Offersen
- European Society of Radiation Oncology (ESTRO) and Department of Experimental Clinical Oncology & Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - S Ohno
- Cancer Institute Hospital, Breast Oncology Centre, Tokyo, Japan
| | - O Pagani
- Institute of Oncology of Southern Switzerland, Geneva University Hospitals, Swiss Group for Clinical Cancer Research (SAKK), International Breast Cancer Study Group (IBCSG), Bellinzona, Switzerland
| | - S Paluch-Shimon
- Oncology Institute, Shaare Zedek Medical Centre, Jerusalem, Israel
| | - F Penault-Llorca
- Department of Pathology, Centre Jean Perrin, Clermont-Ferrand Cedex, France
| | - A Prat
- IDIBAPS (Institut d'Investigacions Biomèdiques August Pi iSunyer), Hospital Clínic of Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumor, Barcelona, Spain
| | - H S Rugo
- Breast Oncology Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G W Sledge
- Oncology Division, Stanford University Medical Center, Stanford, USA
| | - D Spence
- Policy Department, Breast Cancer Network Australia, Camberwell, VIC, Australia
| | - C Thomssen
- Department of Gynaecology, Martin Luther University Halle-Wittenburg, Halle, Germany
| | - D A Vorobiof
- Oncology Department, Sandton Oncology Centre, Johannesburg, South Africa
| | - B Xu
- Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China
| | - L Norton
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York
| | - E P Winer
- Dana-Farber Cancer Institute, Susan Smith Center for Women's Cancers, Breast Oncology Center, Boston, USA
| |
Collapse
|
16
|
Abstract
Aims and Background Interferon (IFN) and interleukin-2 (IL-2) have been proven to be active agents in the treatment of malignant melanoma, but the most effective doses of these cytokines were often associated to important side effects and poor patient compliance. Recently, the subcutaneous administration of low-dose IL-2 was found to be a well-tolerated and effective treatment for renal cancer. Since the combination of low doses of IL-2 and IFN has been hypothesized to have synergistic biologic and cytotoxic effects, we evaluated feasibility and patient compliance of a scheme that combined recombinant IFN-alpha (rIFN-α) (3 million units by intramuscular injection, 3 times a week) plus low-dose IL-2 (9 million IU, 3 to 5 times a week) administered subcutaneously for 2 weeks every 28 days. Results Fifteen patients with disseminated malignant melanoma previously treated with chemotherapy entered the study. All but the first 2 self-administered the therapy at home and were followed in an out-patient setting. None of them required in-patient care for toxicity. No WHO grade 4 side effects were detected; the only grade 3 side effects were fever and asthenia in 5 % of the cycles. Mild hematologic toxicity (grade 2) was observed at the highest weekly dose of IL-2. No major responses were observed in this subset of heavily pretreated patients. Conclusions We conclude that the regimen studied is feasible and well tolerated in an out-patient setting, but it is unlikely to be effective. The good patient compliance makes this schedule eligible to evaluate whether IL-2 plus rIFN-α can enhance the results of chemotherapy in this disease.
Collapse
Affiliation(s)
- F de Braud
- Divisione di Oncologia Medica B, Istituto Nazionale per la Cura e lo Studio dei Tumori, Milano, Italy
| | | | | | | | | |
Collapse
|
17
|
Biganzoli L, Berardi R, Pedersini R, Minisini AM, Caremoli ER, Spazzapan S, Lima JS, Baldari D, Orlando L, Magnolfi E, Pistelli M, Brunello A, Zafarana E, Bernardo A, Leo S, Colleoni M, Donati S, De Placido S, Parolin V, Vitale S, Di Leo A, Puglisi F, Boni L, Cinieri S. Abstract P6-14-01: The effect trial: A randomized phase II trial evaluating two different doses of weekly (W) NAB-paclitaxel (NP) as first-line chemotherapy in older breast cancer (BC) patients (pts). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-14-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: W taxanes (T) are commonly used in the treatment of older BC pts, with neurotoxicity (NTX) and fatigue being dose-limiting toxicities with a possible negative impact on function. No prospective data exists on the safety and efficacy of W NP in this population. NP might be of particular value in older pts, due to no need for premedication with steroids and shorter time to recovery from neurotoxicity than conventional T, resulting in a reduced risk of exacerbation of comorbidities such as hypertension and diabetes, and possibly of functional decline (FD). Methods: Pts aged ≥ 65 years (y) with Her-2 negative or Her-2 positive (+), but contraindicated to anti-Her-2 therapy, advanced BC were randomized to receive NP as first-line chemotherapy at either 100 (Arm A) or 125 mg/m2 (Arm B), days 1, 8, 15 q 28. The primary end-point was event-free survival (EFS). An event was either disease progression (PD), death, or FD - defined as a decrease of at least 1 point from baseline values of activities of daily living (ADL) or instrumental ADL (IADL), deemed by the investigator as treatment-related and confirmed at the subsequent cycle. Secondary endpoints included progression-free survival (PFS), response rate (RR) in pts with measurable disease, and incidence of adverse events (AEs). Results: From January 2013 to September 2016, 160 pts were randomized in 15 Italian centres; all but 2 who never started NP were eligible for final analysis. Pts median age was 72y (range 65-84) in Arm A and 73y (range 65-88) in Arm B. Median ECOG performance status was 0 (range 0-2). Baseline IADL impairment was reported in 20 pts (25%) in both arms. >80% pts had ER+ tumors; 2 pts had HER2+ disease. Visceral disease was present in 71% (Arm A) and 70% (Arm B) of pts. Prior exposure to T in the neo/adjuvant setting was 14% (Arm A) and 13% (Arm B). Median number of delivered cycles of NP was 6 (range 1-28 in Arm A, and 1-22 in Arm B), with 3 pts still on treatment. Dose reductions were similarly reported (72% of pts Arm A, 78% of pts Arm B). At a median follow-up of 21 months (mos) (Interquartile range 14-28.4) 140 events were observed. Arm A/Arm B: PD n=53(67%)/n=52(66%); FD n=13(15%)/n=14(18%), death n=3(4%)n=5(6%). Outcomes data are reported in the following table:
Outcomes Arm AArm BMedian EFS, mos (90% CI)6.2 (5.5-8.4)6.4 (5.8-7.7)Median PFS, mos (95% CI)8.3 (5.9-10.5)8.8 (7.4-10.3)RR (95% CI)37% (25-50)42% (30-54)
Fatigue (Arm A: grade (G)2 29%, G3 11%; Arm B: G2 46%, G3 5%) and NTX (Arm A: G2 15%, G3 4%; Arm B: G2 28%, G3 8%) were the most frequently reported AEs. No G4 AEs were reported with the exception of neutropenia (1 pt in arm A) and leucopenia (3 pts in Arm A, 1 pt in arm B). 1 G5 (sepsis) was recorded in Arm B. NTX was reported as the reason for treatment discontinuation in 21 pts (13%) of whom 16 (21%) in arm B. Conclusion: Looking at classical study endpoints (PFS, RR), both doses of NP are active in older pts. However, 17% of pts had to stop treatment due to FD, assessed according to predefined criteria. Due to similar efficacy and reduced NTX, W NP 100 is the suggested dose to be used in older pts with advanced BC.
Citation Format: Biganzoli L, Berardi R, Pedersini R, Minisini AM, Caremoli ER, Spazzapan S, Lima JS, Baldari D, Orlando L, Magnolfi E, Pistelli M, Brunello A, Zafarana E, Bernardo A, Leo S, Colleoni M, Donati S, De Placido S, Parolin V, Vitale S, Di Leo A, Puglisi F, Boni L, Cinieri S. The effect trial: A randomized phase II trial evaluating two different doses of weekly (W) NAB-paclitaxel (NP) as first-line chemotherapy in older breast cancer (BC) patients (pts) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-14-01.
Collapse
Affiliation(s)
- L Biganzoli
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - R Berardi
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - R Pedersini
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - AM Minisini
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - ER Caremoli
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S Spazzapan
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - JS Lima
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - D Baldari
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - L Orlando
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - E Magnolfi
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - M Pistelli
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - A Brunello
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - E Zafarana
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - A Bernardo
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S Leo
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - M Colleoni
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S Donati
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S De Placido
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - V Parolin
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S Vitale
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - A Di Leo
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - F Puglisi
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - L Boni
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| | - S Cinieri
- Sandro Pitigliani Medical Oncology Unit, Instituto Toscano Tumori, Prato, Italy; Clinica Oncologica – Università Politecnica delle Marche – Ospedali Riuniti di Ancona, Ancona, Italy; Oncologia-Breast Unit Spedali Civili di Brescia, Brescia, Italy; Dipartimento di Area Medica, Università degli Studi di Udine, Udine, Udine, Italy; Oncologia Medica A.O.Papa Giovanni XXIII, Bergamo, Italy; Oncologia Medica B, Centro di Riferimento Oncologico, Istituto Nazionale Tumori, Aviano, Aviano, Italy; Clinical Trials Coordinating Centre, AOU Careggi Instituto Toscano Tumori, Firenze, Italy; Oncologia Medica, Ospedale Perrino, ASL Brindisi Sora, Brindisi, Italy; Oncologia Medica Ospedale Civile SS Trinità di SoraOV Padova, Frosinone, Italy; Oncologia Medica 1 Istituto Oncologico Veneto- IOV Padova, Padova, Italy; Unita Operativa Complessa di Oncologia, Fondazione Maugeri, IRCCS di Pavia, Pavia, Italy; Oncologia Geriatrica, U.O. Oncologia Medica, Ospedale V. Fazzi, Lecce, Italy; Istituto Europeo di Oncologia di Milano, Mila
| |
Collapse
|
18
|
Di Leo A, Risi E, Biganzoli L. No pain, no gain… What we can learn from a trial reporting negative results. Ann Oncol 2018; 28:678-680. [PMID: 28327956 DOI: 10.1093/annonc/mdx065] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Indexed: 01/16/2023] Open
Affiliation(s)
- A Di Leo
- Hospital of Prato, Istituto Toscano Tumori, Sandro Pitigliani, Medical Oncology Department
| | - E Risi
- Hospital of Prato, Istituto Toscano Tumori, Sandro Pitigliani, Medical Oncology Department
| | - L Biganzoli
- Hospital of Prato, Istituto Toscano Tumori, Sandro Pitigliani, Medical Oncology Department
| |
Collapse
|
19
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:3111. [PMID: 28327998 PMCID: PMC5834023 DOI: 10.1093/annonc/mdx036] [Citation(s) in RCA: 136] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
20
|
Pronzato P, Mustacchi G, Riccardi F, Turletti A, Michelotti A, Natoli C, Livi L, Del Mastro L, Donadio M, Garrone O, Giordano M, De Laurentiis M, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Cazzaniga M. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Mustacchi G, Cazzaniga M, Giordano M, Garrone O, Donadio M, Del Mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Riccardi F, Marchetti P, Montemurro F, Romagnoli E, De Placido S, Biganzoli L, Bisagni G, Bria E. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Mustacchi G, Cazzaniga M, Bria E, Bisagni G, Biganzoli L, Pronzato P, De Placido S, Romagnoli E, Montemurro F, Marchetti P, De Laurentiis M, Riccardi F, Turletti A, Michelotti A, Natoli C, Livi L, Del Mastro L, Donadio M, Garrone O, Giordano M. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
23
|
Risi E, Grilli A, Migliaccio I, Biagioni C, Guarducci C, Bonechi M, McCartney A, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L. Gene signatures as potential predictive markers of response to neoadjuvant chemotherapy in ER+/HER2+ breast cancer patients. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx363.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
24
|
Cazzaniga M, Mustacchi G, Giordano M, Garrone O, Donadio M, del mastro L, Livi L, Natoli C, Michelotti A, Turletti A, Ferdinando R, De Laurentiis M, Marchetti P, Montemurro M, Romagnoli E, De Placido S, Pronzato P, Biganzoli L, Bisagni G, Bria E. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
25
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios C, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso M, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart M, Pierga J, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to “3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)” [Breast 31 (February 2017) 244–259]. Breast 2017; 32:269-270. [DOI: 10.1016/j.breast.2017.01.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
26
|
Chow LWC, Biganzoli L, Leo AD, Kuroi K, Han HS, Patel J, Huang CS, Lu YS, Zhu L, Chow CYC, Loo WTY, Glück S, Toi M. Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients. Asia Pac J Clin Oncol 2017; 13:372-378. [PMID: 28371190 DOI: 10.1111/ajco.12682] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2016] [Accepted: 01/30/2017] [Indexed: 12/01/2022]
Abstract
AIM For early-stage breast cancer, four cycles of docetaxel and cyclophosphamide (TC) was proven superior to doxorubicin plus cyclophosphamide in the US Oncology 9375 trial. Given primary prophylactic antibiotics, 5% febrile neutropenia was recorded in a population comprising 75.5% Caucasians. Smaller trials and retrospective studies reviewing TC use in Asian patients did not produce similar incidence rates. This study aims to discover the variable hematological toxicities with TC use in Caucasian and Asian patients. METHODS Breast cancer data was retrospectively reviewed for patients receiving adjuvant docetaxel 60-75 mg/m2 plus cyclophosphamide 600 mg/m2 from six countries (China, Hong Kong, Japan, Taiwan, Italy, and United States). Similar number of patients with relatively balanced baseline characteristics were chosen for analysis of hematological and nonhematological toxicities and survival data. RESULTS From March 2004 to July 2013, data of 227 patients (127 Asians and 100 Caucasian) patients were analyzed for treatment-related toxicities. During the four cycles of TC, Asians had a significantly higher rate of grade ≥2 neutropenia than Caucasians (45.7% vs 6.0%; P <0.001) and significantly more grade ≥3 neutropenia events were documented (respectively 30.7% vs 4.0%, P <0.001). The prophylactic use of G-CSF was similar; 26.0% in Asians and 28.0% in Caucasian (P = 0.764). There were no differences in nonhematological toxicities. No significant difference in disease-free survival was observed between Asians and Caucasians (log-rank P = 0.910). CONCLUSIONS Ethnic differences in toxicity profile exist between Asian and Caucasian patients given adjuvant TC. Over 30% Asians but less than 5% Caucasians experienced grade ≥3 neutropenia.
Collapse
Affiliation(s)
- L W C Chow
- State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute of Applied Medicine and Health, Macau University of Science and Technology, Macau.,Organisation for Oncology and Translational Research, Hong Kong.,UNIMED Medical Institute, Hong Kong
| | - L Biganzoli
- Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Italy
| | - A D Leo
- Sandro Pitigliani Medical Oncology Unit, Hospital of Prato, Italy
| | - K Kuroi
- Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
| | - H S Han
- Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, USA
| | - J Patel
- Department of Women's Oncology, H. Lee Moffitt Cancer Center and Research Institute, USA
| | - C S Huang
- Department of Surgery, National Taiwan University Hospital, Taiwan
| | - Y S Lu
- Department of Oncology, National Taiwan University Hospital, Taiwan
| | - L Zhu
- Department of Surgery, Shanghai Jiao Tong University, Shanghai, China
| | | | - W T Y Loo
- Organisation for Oncology and Translational Research, Hong Kong.,UNIMED Medical Institute, Hong Kong
| | - S Glück
- Sylvester Comprehensive Cancer Center, Leonard M. Miller School of Medicine, University of Miami, USA
| | - M Toi
- Organisation for Oncology and Translational Research, Hong Kong.,Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| |
Collapse
|
27
|
Tryfonidis K, Marreaud S, Khaled H, De Valk B, Vermorken J, Welnicka-Jaskiewicz M, Aalders K, Bartlett JMS, Biganzoli L, Bogaerts J, Cameron D. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study. Breast Cancer Res Treat 2017; 163:507-515. [PMID: 28324265 DOI: 10.1007/s10549-017-4203-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 03/13/2017] [Indexed: 11/28/2022]
Abstract
PURPOSE Cardiotoxicity is a side effect of trastuzumab. We assessed efficacy and cardiac safety of CMF with trastuzumab (CMF+T) in HER2-positive metastatic breast cancer patients (MBC). METHODS In this phase II study, centrally confirmed, previously treated HER2-positive MBC patients with measurable disease (per RECIST v 1.0) were enrolled. Initially, patients were randomized between 8 CMF cycles alone or combined with trastuzumab during chemotherapy, followed by 3-weekly trastuzumab maintenance till progression. A protocol amendment dropped the CMF arm and thereafter all patients received CMF+T. Translational research for prediction of treatment benefit was performed through serial serum HER2-shed antigen assessments. RESULTS Ninety patients (CMF: 19; CMF+T: 71) were enrolled between 2002 and 2006. Median age was 54 years. 42 patients had prior chemotherapy (33 with anthracyclines) and 41/71 patients who received CMF+T continued trastuzumab monotherapy for a median duration of 40 weeks. Overall response rate was 50% for CMF+T (35/70) and 32% for CMF (6/19). Median duration of response was 10.3 months and 5.4 months, respectively. Median progression-free survival was 9.4 months (95% CI 8.1-11.6) and 4.8 months (95% CI 2.8-7.9), respectively. In the CMF+T arm, 13(18%) patients had an absolute LVEF decline, including 3 patients developing any grade of New York Heart Association cardiac dysfunction. Patients with an increase of 30% over baseline shed antigen had a higher progression risk (95% CI 7.6, 3.9-14.8). CONCLUSIONS CMF+T is effective, with an acceptable cardiotoxicity profile. LVEF declines were mostly asymptomatic and occurred irrespective of previous anthracycline exposure. CMF+T can be considered for these patients, if other cytotoxics are contraindicated.
Collapse
Affiliation(s)
| | | | - H Khaled
- Department of Medical Oncology, National Cancer Institute- Cairo University, Cairo, Egypt
| | - B De Valk
- Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands
| | - J Vermorken
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium
| | - M Welnicka-Jaskiewicz
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - K Aalders
- EORTC Headquarters, Brussels, Belgium
| | - J M S Bartlett
- Ontario Institute for Cancer Research, Toronto, Ontario, Canada.,University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK
| | - L Biganzoli
- Department of Medical Oncology, New Hospital of Prato, Istituto Toscano Tumori, Prato, Italy
| | | | - David Cameron
- University of Edinburgh Cancer Research Center, Western General Hospital, Edinburgh, UK.
| | | |
Collapse
|
28
|
Di Leo A, Pestrin M, Siclari O, Sanna G, Moretti E, Biganzoli L. De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer. Breast 2017. [DOI: 10.1016/s0960-9776(17)30100-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
29
|
Mustacchi G, Cazzaniga ME, Biganzoli L, De Laurentiis M, Del Mastro L, De Placido S, Donadio M, Garrone O, Giordano M, Latini L, Livi L, Marchetti P, Michelotti A, Montemurro F, Natoli C, Pronzato P, Riccardi F, Turletti A. Abstract P5-15-07: First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 – AMBRA” Italian study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-15-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Frequency of CHT regimens according to biological subtypes and Setting of treatmentLuminal TumoursSettingRegimenAdj (%)1st-line (%)2nd-line (%)3rd-line (%)anthra-based (w/o Taxanes)44.27.15.19.9Anthra-Taxanes30.52.60.50CMF-like17.50.61.02.1Taxane mono/combo*6.319.314.521.5Pacliataxel + Bevacizumab020.24.33.7Platinum-based03.61.70.8Capecitabine +/- Vinorelbine019.122.217.4Eribuline002.312.4 TNBCSettingRegimenAdj (%)1st-line (%)2nd-line (%)3rd-line (%)Anthra-based (w/o Taxanes)25.73.15.116.2Anthra-Taxanes36.11.100CMF-like8.22.15.10Taxane mono/combo*6.318.417.810.8Paclitaxel + Bevacizumab024.71.70Platinum-based020.622.42.7Capecitabine +/- Vinorelbine025.720.610.8Eribuline003.429.7**Irrespectively of biological subtype, nab-paclitaxel was used in 3.6%, 15.3% and 16.4% of cases in 1st, 2nd and 3rd line, respectively
BACKGROUND
Breast Cancer prognosis improved in the last years due both to early diagnosis and Adj treatments. The choice of CHT regimens should consider previous Adj treatments, pattern of relapse and biological subtype. There are few information on the treatment of MBC in the clinical practice outside controlled trials, last study has been published 15 yrs ago in Italy.
PATIENTS AND METHODS
The GIM13-AMBRA Study is a multicenter longitudinal cohort study, describing the choice of first and subsequent lines of treatment for MBC in HER2-ve pts. We are collecting data of 30 consecutive pts from 42 Italian Centres who developed the first relapse in the years 2012-2015 and were treated with CHT, (+/- previous endocrine treatments (HT)) for MBC. One of the secondary aims is to evaluate the Time to Treatment Change (TTC) (time between treatment start and its change for any reason) as surrogate endpoint for Time To Progression outside clinical trials. The present report is focused on the choice of treatments in any line and TTC, according to biological subtypes. .
RESULTS
For the present analysis, 683 pts are evaluable. Pts with Luminal A and B tumours received CHT and HT in 65.3% (Adjuvant), 21.7% (1st line), 7.1% (2nd line) and 7% (3rd line) of the cases. The most used regimens according to tumour subtype and line of treatment are shown in Table 1.
Median TTC from 1st to 2nd line was 8.1 and 17.9 months in TNBC and Luminal tumours, respectively, whereas TTC from 2nd to 3rd line was 3.1 and 12.9 months, respectively.
CONCLUSION
Preliminary results of the AMBRA-GIM13 Italian observational study confirm that in most cases treatment for MBC is strongly related to the type of the Adj regimen, being the use of anthracyclines marginal in MBC, whereas taxanes are widely used in any line. In 1st line the most used regimens are Taxane and Bevacizumab or Capecitabine/Vinorelbine combinations. The last one remains the most used CHT in 2nd and 3rd lines. No difference have been observed according to biological subtype, except for Platinum-based regimens in TNBC. HT alone remains the preferred choice in 1st and 2nd line in Luminal cases. TTC seems to be a reliable surrogate for PFS in the “real world” practice . CHT still plays a crucial role in the treatment of MBC HER2-ve pts.
Citation Format: Mustacchi G, Cazzaniga ME, Biganzoli L, De Laurentiis M, Del Mastro L, De Placido S, Donadio M, Garrone O, Giordano M, Latini L, Livi L, Marchetti P, Michelotti A, Montemurro F, Natoli C, Pronzato P, Riccardi F, Turletti A. First and further line choices of treatment for HER2-VE metastatic breast cancer (MBC) according to adjuvant treatment and biological subtype. Preliminary results of the observational “GIM-13 – AMBRA” Italian study [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-15-07.
Collapse
Affiliation(s)
- G Mustacchi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - ME Cazzaniga
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Biganzoli
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M De Laurentiis
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Del Mastro
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - S De Placido
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M Donadio
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - O Garrone
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - M Giordano
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Latini
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - L Livi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - P Marchetti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - A Michelotti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - F Montemurro
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - C Natoli
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - P Pronzato
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - F Riccardi
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| | - A Turletti
- Università di Trieste; ASST Monza; Ospedale Santo Stefano Oncologia Medica; INT - Fondazione G. Pascale; I.R.C.C.S. A.O.U. San Martino - I.S.T.; A.O.U. Federico II; A.O.U. Citta della Salute e della Scienza Oncologia Medica Senologica; A.O. S. Croce e Carle di Cuneo - P.O. Carle Oncologia; ASST Lariana - Ospedale S. Anna U.O. di Oncologia Medica; Ospedale di Macerata U.O. Oncologia; A.O.U. Careggi Radioterapia; Azienda Ospedaliera Sant' Andrea U.O.C. Oncologia; Azienda Ospedaliera Pisana U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - Istituto di Ricovero e Cura a Carattere Scientifico (I.R.C.C.S.) Direzione di Oncologia Clinica; Policlinico 'SS. Annunziata' Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 D.H. Oncologia
| |
Collapse
|
30
|
Krop I, Abramson V, Colleoni M, Holmes FA, Estevez L, Hart L, Awada A, Zamagni C, Morris P, Schwartzberg L, Chan S, Wheatley D, Guculp A, Biganzoli L, Steinberg J, Gianni L, Trudeau M, Kelly CM, Uppal H, Tudor IC, Peterson A, Winer E, Yardley DA. Abstract P2-08-01: Results from a randomized placebo-controlled phase 2 trial evaluating exemestane ± enzalutamide in patients with hormone receptor–positive breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- I Krop
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - V Abramson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Colleoni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - FA Holmes
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Estevez
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Hart
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Awada
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - C Zamagni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - P Morris
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Schwartzberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - S Chan
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - D Wheatley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Guculp
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Biganzoli
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - J Steinberg
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - L Gianni
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - M Trudeau
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - CM Kelly
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - H Uppal
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - IC Tudor
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - A Peterson
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - E Winer
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| | - DA Yardley
- Dana Farber Cancer Institute, Boston, MA; Vanderbilt University, Nashville, TN; Istituto Europeo di Oncologia, Milan, Italy; Texas Oncology-Houston Memorial City, Houston, TX; Centro Integral Oncológico Clara Campal, Hospital de Madrid Norte-Sanchinarro, Madrid, Spain; Florida Cancer Specialists, Ft. Myers, FL; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi, Bologna, Italy; Beaumont Hospital, Dublin, Ireland; The University of Tennessee, West Cancer Center, Memphis, TN; Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Royal Cornwall Hospitals NHS Trust-Sunrise Centre, Cornwall, United Kingdom; Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell College of Medicine, New York, NY; Nuovo Ospedale di Prato, Italy; Astellas Pharma, Inc., Northbrook, IL; Ospedale San Raffaele, Milan, Italy; Sunnybrook Health Sciences Centre, Toronto, Canada; All Ireland Collaborative Oncoology
| |
Collapse
|
31
|
Cazzaniga ME, Mustacchi G, De Laurentiis M, Garrone O, Donadio M, Del Mastro L, Latini L, Livi L, Michelotti A, Montemurro F, Natoli C, Riccardi N, Turletti A, Giordano M, De Placido S, Biganzoli L, Pronzato P, Marchetti P. Abstract P5-14-09: Luminal A breast cancer: Is it really a “good prognosis” disease? Prelimary results of the GIM-13 - AMBRA study. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-14-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the symposium.
Collapse
Affiliation(s)
- ME Cazzaniga
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - G Mustacchi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M De Laurentiis
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - O Garrone
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M Donadio
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Del Mastro
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Latini
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Livi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - A Michelotti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - F Montemurro
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - C Natoli
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - N Riccardi
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - A Turletti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - M Giordano
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - S De Placido
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - L Biganzoli
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - P Pronzato
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| | - P Marchetti
- ASST Monza - Ospedale San Gerardo, Monza, MB, Italy; Università degli Studi di Trieste, Trieste, TS, Italy; INT - Fondazione G. Pascale - S.C. Oncologia Medica Senologica- Dipartimento di Senologia; Azienda Ospedaliero Universitaria Federico II - Dipartimento di Medicina Clinica e Chirurgia - Oncologia Medica; A.O.U. Citta della Salute e della Scienza - Oncologia Medica Senologica; I.R.C.C.S. A.O.U. San Martino - I.S.T. - S.S. Sviluppo Terapie Innovative - Oncologia Medica A; Ospedale di Macerata - U.O. Oncologia; A.O.U. Careggi - Radioterapia; Azienda Ospedaliera Pisana - U.O. Oncologia Medica I; Fondazione del Piemonte per l'Oncologia - I.R.C.C.S. - Direzione di Oncologia Clinica Investigativa (INCO); Policlinico “SS. Annunziata” - Chieti - Clinica Oncologica; Azienda Ospedaliera 'A. Cardarelli' (AORN) - U.O.C. Oncologia; Presidio Ospedaliero Martini - ASL TO1 - D.H.Oncologia; Ospedale Santo Stefano - Oncologia Medica; Azienda Ospedaliera S.Croce e Carle - Oncologia; ASST Lariana - Ospedale S. Anna - U.O
| |
Collapse
|
32
|
Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 2017; 28:16-33. [PMID: 28177437 PMCID: PMC5378224 DOI: 10.1093/annonc/mdw544] [Citation(s) in RCA: 258] [Impact Index Per Article: 36.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Affiliation(s)
- F. Cardoso
- European School of Oncology & Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - A. Costa
- European School of Oncology, Milan, Italy and European School of Oncology, Bellinzona, Switzerland
| | - E. Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M. Aapro
- Breast Center, Genolier Cancer Center, Genolier, Switzerland
| | - F. André
- Department of Medical Oncology, Gustave Roussy Institute, Villejuif, France
| | - C. H. Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J. Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | | | - L. Biganzoli
- Medical Oncology Department, Hospital of Prato, Prato, Italy
| | - M. J. Cardoso
- Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal
| | - L. Carey
- Department of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center
| | | | - G. Curigliano
- Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy
| | - V. Dieras
- Department of Medical Oncology, Institut Curie, Paris, France
| | - N. El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut, Beirut, Lebanon
| | - A. Eniu
- Department of Breast Tumors, Cancer Institute ‘I. Chiricuta’, Cluj-Napoca, Romania
| | - L. Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D. Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P. Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K. Gelmon
- BC Cancer Agency, Vancouver Cancer Centre, Vancouver, Canada
| | - A. Gennari
- Department of Medical Oncology, Galliera Hospital, Genoa, Italy
| | - N. Harbeck
- Brustzentrum der Universitat München, Munich, Germany
| | - C. Hudis
- Breast Medicine Service, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - B. Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I. Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
| | - M. Mayer
- Advanced Breast Cancer.org, New York, USA
| | - H. Meijer
- Department of Radiation Oncology, Radvoud University Medical Center, Nijmegen, The Netherlands
| | - S. Mertz
- Metastatic Breast Cancer Network US, Inversness, USA
| | - S. Ohno
- Breast Oncology Centre, Cancer Institute Hospital, Tokyo, Japan
| | - O. Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | | | - F. Peccatori
- European School of Oncology, Milan, Italy and Bellinzona, Switzerland
| | - F. Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M. J. Piccart
- Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - J. Y. Pierga
- Department of Medical Oncology, Institut Curie-Université Paris Descartes, Paris, France
| | - H. Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - L. Shockney
- Department of Surgery and Oncology, Johns Hopkins Breast Center, Baltimore
| | - G. Sledge
- Indiana University Medical CTR, Indianapolis
| | - S. Swain
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, USA
| | - C. Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - A. Tutt
- Breakthrough Breast Cancer Research Unit, King’s College London and Guy’s and St Thomas’s NHS Foundation Trust, London, UK
| | - D. Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - B. Xu
- Department of Medical Oncology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - L. Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York
| | - E. Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
33
|
Hart C, Vignoli A, Tenori L, Biganzoli L, Risi E, Love R, Luchinat C, Di Leo A. Serum metabolomic profiles identify ER-positive early breast cancer patients at increased risk of disease recurrence in a multicentre population. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw364.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Di Donato S, Mislang A, Vignoli A, Mori E, Vitale S, Biagioni C, Hart C, Becheri D, Del Monte F, Luchinat C, Di Leo A, Mottino G, Tenori L, Biganzoli L. Serum metabolomic as biomarkers to differentiate early from metastatic disease in elderly colorectal cancer (crc) patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.20] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Sanna G, Mislang A, Pestrin M, Biagioni C, Risi E, Cappadona S, Moretti E, Gabellini S, Di Leo A, Biganzoli L. A single centre pilot study aiming to determine the recommended dose (RD) of metronomic oral vinorelbine in combination with oral cyclophosphamide and bevacizumab in advanced breast cancer (ABC) patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
36
|
Loi S, Andre F, Maibach R, Hui R, Bartsch R, Jerusalem G, Gombos A, Campone M, Bonnefoi H, Bachelot T, Curigliano G, Biganzoli L, Giobbie-Hurder A. Abstract OT3-01-05: PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-ot3-01-05] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Preclinical and correlative clinical data suggest that HER2-positive breast cancer could be amenable to immunotherapeutic approaches. We hypothesize that immune evasion contributes to tumor growth and progression in HER2-positive tumors and anti-PD1 restores T cell cytotoxicity reverting trastuzumab resistance.
Eligibility criteria
Patients with HER2-positive, PD-L1 expressing, unresectable loco-regional or metastatic breast cancer with disease progression during treatment with trastuzumab or subsequent anti-HER2 therapy of not more than 3 lines.
HER2 overexpression and PD-L1 expression confirmed in central laboratories based on tissue obtained within 1 year prior to study entry.
Objective
The primary objectives of this phase Ib/II study are to determine the recommended dose (RP2D) of pembrolizumab in combination with standard dose trastuzumab, and to evaluate the efficacy and safety profile of the drug combination in patients with PD-L1 positive, HER2 overexpressing unresectable loco-regional or metastatic breast cancer.
Trial design
The phase Ib portion of the trial will use a standard 3+3 design to determine the RP2D of standard-dose trastuzumab with three pembrolizumab dose levels: 2 mg/kg, 10 mg/kg, or a fall-back dose of 1 mg/kg. A Simon optimal two-stage design will be used in the phase II portion to assess the primary outcome of objective response. Pembrolizumab at the RP2D will be given with trastuzumab (6 mg/kg i.v. every 3 weeks) until disease progression or lack of tolerability. The null hypothesis that the true objective response rate (ORR) is 7% will be tested against a one-sided alternative rate of 22%. In the first stage, 17 patients will be enrolled. If there are zero or one responses, enrollment will stop. Otherwise, 23 additional patients will be accrued. The null hypothesis will be rejected if 6 or more objective responses are observed in 40 evaluable patients. This design has a type-I error of 0.05 and 85% power. If the null hypothesis is true, the probability is 0.66 that enrollment will stop at the end of the first stage.
Two concurrent analyses of the data will take place at the end of the first stage. One analysis will assess ORR using the criteria described above. The second will be a detailed review of safety data.
Statistical methods
Primary and secondary endpoints will be based on patients enrolled in the phase II trial. ORR will be presented with a two-sided 90% confidence interval calculated using the method of Atkinson and Brown. The distributions of time-to-event secondary endpoints, such as duration of response and time to progression, will be summarized using the method of Kaplan-Meier.
Present accrual and target accrual
As of 3 June 2015 11 patients have been screened for HER2 and PD-L1 positivity, and 3 successfully enrolled, completing the first dose cohort. Target enrollment of this phase Ib/II trial is 6-46 evaluable patients. Discussions are ongoing to include a PD-L1 negative cohort.
Contact information
Conducted by the International Breast Cancer Study Group and the Breast International Group in collaboration with Merck Sharp & Dohme Corp.
Citation Format: Loi S, Andre F, Maibach R, Hui R, Bartsch R, Jerusalem G, Gombos A, Campone M, Bonnefoi H, Bachelot T, Curigliano G, Biganzoli L, Giobbie-Hurder A. PANACEA (IBCSG 45-13/BIG 4-13): A phase Ib/II trial evaluating the efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant, HER2-positive, metastatic breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr OT3-01-05.
Collapse
Affiliation(s)
- S Loi
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - F Andre
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - R Maibach
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - R Hui
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - R Bartsch
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - G Jerusalem
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - A Gombos
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - M Campone
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - H Bonnefoi
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - T Bachelot
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - G Curigliano
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - L Biganzoli
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| | - A Giobbie-Hurder
- International Breast Cancer Study Group and Breast International Group, Bern, Switzerland
| |
Collapse
|
37
|
Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev 2016; 43:19-26. [DOI: 10.1016/j.ctrv.2015.11.009] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2015] [Revised: 11/24/2015] [Accepted: 11/25/2015] [Indexed: 10/22/2022]
|
38
|
Biganzoli L, Lichtman S, Michel JP, Papamichael D, Quoix E, Walko C, Aapro M. Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG). Eur J Cancer 2015; 51:2491-500. [DOI: 10.1016/j.ejca.2015.08.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 08/09/2015] [Indexed: 10/23/2022]
|
39
|
Roberts A, Biganzoli L, Becheri D, Mottino G, Mossello E, Di Bari M. P-157: Physical performance measures compare favorably with geriatric assessment in elderly oncological patients. Eur Geriatr Med 2015. [DOI: 10.1016/s1878-7649(15)30257-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
40
|
Biganzoli L, Falbo A, Forte F, Grosso M, Rigamonti L. Mass balance and life cycle assessment of the waste electrical and electronic equipment management system implemented in Lombardia Region (Italy). Sci Total Environ 2015; 524-525:361-375. [PMID: 25913003 DOI: 10.1016/j.scitotenv.2015.04.041] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Revised: 03/31/2015] [Accepted: 04/12/2015] [Indexed: 06/04/2023]
Abstract
Waste electrical and electronic equipment (WEEE) is one of the fastest growing waste streams in Europe, whose content of hazardous substances as well as of valuable materials makes the study of the different management options particularly interesting. The present study investigates the WEEE management system in Lombardia Region (Italy) in the year 2011 by applying the life cycle assessment (LCA) methodology. An extensive collection of primary data was carried out to describe the main outputs and the energy consumptions of the treatment plants. Afterwards, the benefits and burdens associated with the treatment and recovery of each of the five categories in which WEEE is classified according to the Italian legislation (heaters and refrigerators - R1, large household appliances - R2, TV and monitors - R3, small household appliances - R4 and lighting equipment - R5) were evaluated. The mass balance of the treatment and recovery system of each of the five WEEE categories showed that steel and glass are the predominant streams of materials arising from the treatment; a non-negligible amount of plastic is also recovered, together with small amounts of precious metals. The LCA of the regional WEEE management system showed that the benefits associated with materials and energy recovery balance the burdens of the treatment processes, with the sole exception of two impact categories (human toxicity-cancer effects and freshwater ecotoxicity). The WEEE categories whose treatment and recovery resulted more beneficial for the environment and the human health are R3 and R5. The contribution analysis showed that overall the main benefits are associated with the recovery of metals, as well as of plastic and glass. Some suggestions for improving the performance of the system are given, as well as an indication for a more-in-depth analysis for the toxicity categories and a proposal for a new characterisation method for WEEE.
Collapse
Affiliation(s)
- L Biganzoli
- Politecnico di Milano, Department of Civil and Environmental Engineering, Piazza L. da Vinci 32, 20133 Milano, Italy.
| | - A Falbo
- Politecnico di Milano, Department of Civil and Environmental Engineering, Piazza L. da Vinci 32, 20133 Milano, Italy
| | - F Forte
- Politecnico di Milano, Department of Civil and Environmental Engineering, Piazza L. da Vinci 32, 20133 Milano, Italy
| | - M Grosso
- Politecnico di Milano, Department of Civil and Environmental Engineering, Piazza L. da Vinci 32, 20133 Milano, Italy
| | - L Rigamonti
- Politecnico di Milano, Department of Civil and Environmental Engineering, Piazza L. da Vinci 32, 20133 Milano, Italy
| |
Collapse
|
41
|
Guarducci C, Bonechi M, Biagioni C, Malorni L, Biganzoli L, Truglia M, Vitale S, Soldi G, Di Leo A, Migliaccio I. Low hormone receptor (HR) status and the benefit of hormonal therapy (HT) in patients with early breast cancer (EBC). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv117.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†. Ann Oncol 2014; 25:1871-1888. [PMID: 25234545 PMCID: PMC4176456 DOI: 10.1093/annonc/mdu385] [Citation(s) in RCA: 284] [Impact Index Per Article: 28.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/11/2014] [Indexed: 12/23/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, AROME, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, Denmark
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| |
Collapse
|
43
|
Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van't Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 2014; 23:489-502. [PMID: 25244983 DOI: 10.1016/j.breast.2014.08.009] [Citation(s) in RCA: 194] [Impact Index Per Article: 19.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2014] [Accepted: 08/12/2014] [Indexed: 12/25/2022] Open
Affiliation(s)
- F Cardoso
- European School of Oncology & Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal.
| | - A Costa
- European School of Oncology, Milan, Italy; European School of Oncology, Bellinzona, Switzerland
| | - L Norton
- Breast Cancer Program, Memorial Sloan-Kettering Cancer Centre, New York, USA
| | - E Senkus
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | - M Aapro
- Division of Oncology, Institut Multidisciplinaire d'Oncologie, Genolier, Switzerland
| | - F André
- Department of Medical Oncology, Gustave-Roussy Institute, Villejuif, France
| | - C H Barrios
- Department of Medicine, PUCRS School of Medicine, Porto Alegre, Brazil
| | - J Bergh
- Department of Oncology/Radiumhemmet, Karolinska Institutet & Cancer Center Karolinska and Karolinska University Hospital, Stockholm, Sweden
| | - L Biganzoli
- Department of Medical Oncology, Sandro Pitigliani Oncology Centre, Prato, Italy
| | - K L Blackwell
- Breast Cancer Clinical Program, Duke Cancer Institute, Durham, USA
| | - M J Cardoso
- Breast Unit, Champalimaud Cancer Center, Lisbon, Portugal
| | - T Cufer
- University Clinic Golnik, Medical Faculty Ljubljana, Ljubljana, Slovenia
| | - N El Saghir
- NK Basile Cancer Institute Breast Center of Excellence, American University of Beirut Medical Center, Beirut, Lebanon
| | - L Fallowfield
- Brighton & Sussex Medical School, University of Sussex, Falmer, UK
| | - D Fenech
- Breast Care Support Group, Europa Donna Malta, Mtarfa, Malta
| | - P Francis
- Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - K Gelmon
- BC Cancer Agency, Vancouver, Canada
| | - S H Giordano
- Departments of Health Services Research and Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, USA
| | - J Gligorov
- APHP Tenon, IUC-UPMC, Francilian Breast Intergroup, Arome, Paris, France
| | - A Goldhirsch
- Program of Breast Health, European Institute of Oncology, Milan, Italy
| | - N Harbeck
- Brustzentrum der Universität München, Munich, DE, USA
| | - N Houssami
- Screening and Test Evaluation Program, School of Public Health, Sydney Medical School, University of Sydney, Sydney, Australia
| | - C Hudis
- Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - B Kaufman
- Sheba Medical Center, Tel Hashomer, Israel
| | - I Krop
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | - U N Lin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | - M Mayer
- Advanced BC.org, New York, USA
| | - S D Merjaver
- University of Michigan Medical School and School of Public Health, Ann Arbor, USA
| | - E B Nordström
- Europa Donna Sweden & Bröstcancerföreningarnas Riksorganisation, BRO, Sundbyberg, Sweden
| | - O Pagani
- Oncology Institute of Southern Switzerland and Breast Unit of Southern Switzerland, Bellinzona, Switzerland
| | - A Partridge
- Department Medical Oncology, Division of Women's Cancers, Dana-Farber Cancer Institute, Boston, USA
| | - F Penault-Llorca
- Jean Perrin Centre, Comprehensive Cancer Centre, Clermont Ferrand, France
| | - M J Piccart
- Department of Medicine, Institut Jules Bordet, Brussels, Belgium
| | - H Rugo
- Department of Medicine, Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - G Sledge
- Indiana University Medical CTR, Indianapolis, USA
| | - C Thomssen
- Department of Gynaecology, Martin-Luther-University Halle-Wittenberg, Halle an der Saale, DE, Germany
| | - L Van't Veer
- Breast Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, USA
| | - D Vorobiof
- Sandton Oncology Centre, Johannesburg, South Africa
| | - C Vrieling
- Department of Radiotherapy, Clinique des Grangettes, Geneva, Switzerland
| | - N West
- Nursing Division, Health Board, Cardiff and Vale University, Cardiff, UK
| | - B Xu
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
| | - E Winer
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA
| | | | | |
Collapse
|
44
|
Turner N, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013; 24:2224-35. [DOI: 10.1093/annonc/mdt196] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Wilson ARM, Marotti L, Bianchi S, Biganzoli L, Claassen S, Decker T, Frigerio A, Goldhirsch A, Gustafsson EG, Mansel RE, Orecchia R, Ponti A, Poortmans P, Regitnig P, Rosselli Del Turco M, Rutgers EJT, van Asperen C, Wells CA, Wengström Y, Cataliotti L. The requirements of a specialist Breast Centre. Eur J Cancer 2013; 49:3579-87. [PMID: 23968730 DOI: 10.1016/j.ejca.2013.07.017] [Citation(s) in RCA: 119] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2013] [Accepted: 07/16/2013] [Indexed: 01/30/2023]
Abstract
INTRODUCTION In recognition of the advances and evidence based changes in clinical practice that have occurred in recent years and taking into account the knowledge and experience accumulated through the voluntary breast unit certification programme, Eusoma has produced this up-dated and revised guidelines on the requirements of a Specialist Breast Centre (BC). METHODS The content of these guidelines is based on evidence from the recent relevant peer reviewed literature and the consensus of a multidisciplinary team of European experts. The guidelines define the requirements for each breast service and for the specialists who work in specialist Breast Centres. RESULTS The guidelines identify the minimum requirements needed to set up a BC, these being an integrated Breast Centre, dealing with a sufficient number of cases to allow effective working and continuing expertise, dedicated specialists working with a multidisciplinary approach, providing all services throughout the patients pathway and data collection and audit. It is essential that the BC also guarantees the continuity of care for patients with advanced (metastatic) disease offering treatments according to multidisciplinary competencies and a high quality palliative care service. The BC must ensure that comprehensive support and expertise may be needed, not only through the core BC team, but also ensure that all other medical and paramedical expertise that may be necessary depending on the individual case are freely available, referring the patient to the specific care provider depending on the problem. CONCLUSIONS Applying minimum requirements and quality indicators is essential to improve organisation, performance and outcome in breast care. Efficacy and compliance have to be constantly monitored to evaluate the quality of patient care and to allow appropriate corrective actions leading to improvements in patient care.
Collapse
|
46
|
Sanna G, Pestrin M, Zafarana E, Biagioni C, Cavaciocchi D, Turner N, Di Leo A, Biganzoli L. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients. Breast 2013; 22:926-32. [PMID: 23707082 DOI: 10.1016/j.breast.2013.04.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2012] [Revised: 04/09/2013] [Accepted: 04/20/2013] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Although dose-dense chemotherapy may reduce breast cancer recurrence and death, phase II studies show that dose-dense docetaxel is poorly tolerated following administration of dose-dense anthracycline-based chemotherapy mainly because of cutaneous toxicity. MATERIAL AND METHODS This pilot study was designed to explore feasibility and safety of dose-dense docetaxel after conventional anthracycline-based therapy. Treatment consisted of sequential administration of 4 cycles of 3-weekly epirubicin (90 mg/m(2)) plus cyclophosphamide (600 mg/m(2)), followed by 4 cycles of bi-weekly docetaxel with pelfilgrastim on day 2 of each docetaxel cycle. Two docetaxel dose levels were planned: 75 mg/m(2) (D75) and 100 mg/m(2) (D100). Patients could only be assigned to the higher docetaxel dose if no early treatment discontinuations due to toxicity were seen, and a median relative dose intensity of docetaxel >90% among the first 5 evaluable patients was achieved. RESULTS Fifty three patients received 4 cycles of epirubicin/cyclophosphamide (EC). Six patients withdrew from study before commencing docetaxel: four for toxicity, and two who declined further study participation. Eight patients, 2 in the first dose level and 6 in the second dose level, stopped treatment for toxicity after the first cycle of docetaxel and before densification. Therefore these events were not considered early treatment discontinuations. No patients required dose interruption after the second docetaxel administration. Overall 5 patients in the first dose level and 34 patients in the second dose level received 4 cycles of accelerated (dose-dense) docetaxel. No grade 3 or grade 4 toxicities occurred at the first dose level. No grade 4 toxicities occurred at the second dose level, while grade 3 toxicities occurring in >2 patients were myalgia and bone pain (5 and 8 patients respectively, 13% and 20%) and skin-nail toxicity (7 patients, 21%). No dose-reductions or significant treatment delays were required, translating to median relative dose intensity of 100% for docetaxel 75 mg/m(2), and 99% for 100 mg/m(2). CONCLUSIONS Administration of docetaxel 100 mg/m(2) bi-weekly after conventional EC is feasible in selected early breast cancer patients. Lack of prior exposure to dose-dense anthracycline, as well as the use of stringent criteria implemented in the treatment protocol, might explain the improved safety profile and high treatment compliance observed in this study.
Collapse
Affiliation(s)
- G Sanna
- "Sandro Pitigliani" Department of Medical Oncology, Hospital of Prato, Istituto Toscano Tumori, 59100 Prato, Italy
| | | | | | | | | | | | | | | |
Collapse
|
47
|
Biganzoli L, Boni L, Becheri D, Zafarana E, Biagioni C, Cappadona S, Bianchini E, Oakman C, Magnolfi SU, Di Leo A, Mottino G. Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool? Ann Oncol 2013; 24:494-500. [PMID: 23045516 DOI: 10.1093/annonc/mds331] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023] Open
Abstract
BACKGROUND A geriatric screening tool would be valuable to identify elderly cancer patients who might benefit from a comprehensive geriatric assessment (CGA). This study evaluated the accuracy of the cardiovascular health study (CHS) instrument in predicting abnormality in CGA. The vulnerable elders' survey-13 (VES-13) was also evaluated. PATIENTS AND METHODS Patients aged ≥ 70 years with solid tumors underwent a CGA after being screened with the CHS and VES-13. Analyses were conducted for the overall population and according to the disease status (early or advanced) and type of early cancer (breast or gastrointestinal, GI). RESULTS Of 259 patients, 75% were impaired according to the CHS and 47% according to the VES-13. CGA impairment was reported in 171 patients (66%). In the overall population, overall accuracy, sensitivity and specificity of CHS in identifying CGA impairments were 74%, 87% and 49%, respectively. The corresponding figures for the VES-13 were 68%, 62% and 81%. Sensitivity and specificity of CHS in predicting CGA impairments in subgroups were early 81% and 55%, advanced 98% and 29%; early breast 78% and 69%, early GI 87.5% and 19%. CONCLUSIONS The CHS compared favourably with VES-13 for sensitivity. However, the great variability in specificity observed with the CHS within subgroups limits its applicability in the global population.
Collapse
Affiliation(s)
- L Biganzoli
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato.
| | - L Boni
- Clinical Trials Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence
| | - D Becheri
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - E Zafarana
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - C Biagioni
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - S Cappadona
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - E Bianchini
- Clinical Trials Coordinating Center, AOU Careggi, Istituto Toscano Tumori, Florence
| | - C Oakman
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - S U Magnolfi
- Geriatric Medicine Unit, Hospital of Prato, Prato, Italy
| | - A Di Leo
- Sandro Pitigliani Medical Oncology Unit, Department of Oncology, Hospital of Prato, Istituto Toscano Tumori, Prato
| | - G Mottino
- Geriatric Medicine Unit, Hospital of Prato, Prato, Italy
| |
Collapse
|
48
|
Colloca⁎ G, Carreca I, Monfardini S, Gambardella A, Biganzoli L, Barbieri V, Castagneto B, Scandurra G, Tirelli U, Bernabei R, Cova D, Condemi G. Assessment and treatment of elderly people with cancer: Italian (AIOM–SIGG) onco-geriatric survey results. J Geriatr Oncol 2012. [DOI: 10.1016/j.jgo.2012.10.077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
49
|
Biganzoli L, Oakman C. 19 Breast Cancer in the Elderly. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)70087-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
50
|
Biganzoli L, Di Vincenzo E, Jiang Z, Lichinitser M, Shen Z, Delva R, Bogdanova N, Vivanco GL, Chen Z, Cheng Y, Just M, Espié M, Vinholes J, Hamm C, Crivellari D, Chmielowska E, Semiglazov V, Dalenc F, Smith I. First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study. Ann Oncol 2012; 23:111-118. [PMID: 21444356 DOI: 10.1093/annonc/mdr043] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND There are limited data on treatment outcomes in the growing population of elderly patients with locally recurrent/metastatic breast cancer (LR/mBC). To gain information on first-line bevacizumab combined with chemotherapy in the elderly, we analyzed data from the ATHENA trial in routine oncology practice. PATIENTS AND METHODS Patients with human epidermal growth factor receptor-2-negative LR/mBC received first-line bevacizumab with standard chemotherapy until disease progression, unacceptable toxicity, or physician/patient decision. We carried out a subgroup analysis of safety and efficacy in patients aged≥70 years. Possible correlations between tolerability and baseline comorbidities or Eastern Cooperative Oncology Group status were explored. RESULTS Bevacizumab was combined with single-agent paclitaxel in 46% of older patients. Only hypertension and proteinuria were more common in older than in younger patients (grade≥3 hypertension: 6.9% versus 4.2%, respectively; grade≥3 proteinuria: 4.0% versus 1.5%, respectively). Grade≥3 arterial/venous thromboembolism occurred in 2.9% versus 3.3%, respectively. Further analysis revealed no relationship between baseline presence and severity of hypertension and risk of developing hypertension during bevacizumab-containing therapy. Median time to progression was 10.4 months in patients aged≥70 years. CONCLUSIONS These findings suggest that bevacizumab-containing therapy is tolerable and active in patients aged≥70 years. Hypertension was more common than in younger patients but was manageable. We find no evidence precluding the use of bevacizumab in older patients, including those with hypertension, although age may influence chemotherapy choice.
Collapse
Affiliation(s)
- L Biganzoli
- 'Sandro Pitigliani' Medical Oncology Unit, Prato Hospital, Istituto Toscano Tumori, Prato.
| | | | - Z Jiang
- Department of Breast Cancer, Beijing 307 Hospital, Beijing, China
| | - M Lichinitser
- Department of Combined Modality Treatment and Chemotherapy of Malignant Tumors, N. N. Blokhin Russian Oncology Research Center, Moscow, Russia
| | - Z Shen
- Department of Breast Surgery, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - R Delva
- Paul Papin Centre, Angers, France
| | - N Bogdanova
- State Institution P.A. Herzen Moscow, Cancer Research Institute, Moscow, Russia
| | - G L Vivanco
- Medical Oncology Department, Cruces Hospital, Barakaldo, Spain
| | - Z Chen
- Department of Medical Oncology, First Affiliated Hospital of Anhui Medical University, He Fei
| | - Y Cheng
- Department of Internal Medicine, Jilin Cancer Hospital, Changchun, China
| | - M Just
- Internal Medicine Practice, Bielefeld, Germany
| | - M Espié
- Breast Disease Centre, Hôpital Saint Louis, Paris, France
| | | | - C Hamm
- Department of Oncology, University of Western Ontario, Windsor, Canada
| | - D Crivellari
- Division of Medical Oncology, National Cancer Institute, Centro di Riferimento Oncologico, Aviano, Italy
| | - E Chmielowska
- Department of Clinical Oncology, Bydgoszcz Oncology Centre, Bydgoszcz, Poland
| | - V Semiglazov
- Breast Cancer Department, N. N. Petrov Research Institute of Oncology, St Petersburg, Russia
| | - F Dalenc
- Department of Medical Oncology, Claudius Regaud Institute, Toulouse, France
| | - I Smith
- Breast Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK
| |
Collapse
|